SCHEMBL20545819

SCHEMBL20545819

Cc1cccc(-c2cccc([C@@H](N)CC(=O)O)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSA P10619 8/20 0.56
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MME P08473 1/20 0.46
SLC6A9 P48067 1/20 0.45
DHODH Q02127 1/20 0.44
CFD P00746 2/20 0.42
TPSB2 P20231 2/20 0.42
ANPEP P15144 1/20 0.42
ENPEP Q07075 1/20 0.42
CYP26A1 O43174 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
F11 P03951 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20545820 1.00 CTSA (0.56) CTSAKMT2ASMN1; SMN2MMESLC6A9
SCHEMBL20545398 0.93 CTSA (0.49) CTSAKMT2ASMN1; SMN2DHODHCFD
SCHEMBL20545395 0.93 CTSA (0.49) CTSAKMT2ASMN1; SMN2DHODHCFD
SCHEMBL27347770 0.91 KMT2A (0.55) CTSAKMT2ASMN1; SMN2SLC6A9ANPEP
SCHEMBL3510648 0.91 KMT2A (0.55) CTSAKMT2ASMN1; SMN2SLC6A9ANPEP
SCHEMBL2858374 0.91 KMT2A (0.55) CTSAKMT2ASMN1; SMN2SLC6A9ANPEP
SCHEMBL20546398 0.90 CTSA (0.49) CTSAKMT2ASMN1; SMN2MMEDHODH
SCHEMBL20546396 0.90 CTSA (0.49) CTSAKMT2ASMN1; SMN2MMEDHODH
SCHEMBL20546132 0.87 KMT2A (0.58) CTSAKMT2ASMN1; SMN2SLC6A9CFD
SCHEMBL20546130 0.87 KMT2A (0.58) CTSAKMT2ASMN1; SMN2SLC6A9CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 EP disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 US disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 CTSA 2240/4885KMT2A 4455/4885SMN1; SMN2 2021/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 CTSA 2240/4885KMT2A 4455/4885SMN1; SMN2 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.